Businesses, of course, face risk every day, whether from supply chain disruption, calamity, or as we’ve seen from a series of hurricanes of the last years, Mother Nature. But most of these risks have a foreseeable ending – after all, at some point the hurricane passes.
But among the many business risks during this Covid age are the unknown risks – how long will the pandemic endure? Which geographies will be hit hardest? What might recovery look like?
And while the insurance business can account for many of the regular risks, Covid brings a new, challenging dimension.
So how are the insurance companies thinking about Covid-19? Perhaps more significantly, how can businesses measure, plan, and account for the risks they face? How should they think about the problem?
Research shows that when chemotherapy is delayed, a patient’s chance of survival falls significantly. Dr. Mariana Chavez MacGregor, a BCRF investigator since 2018, joined our podcast to talk about her work with underserved and underinsured patients—those who are most likely to experience delays—to develop personalized ways to improve healthcare access and, ultimately, outcomes.
Dr. MacGregor is an associate professor at the University of Texas MD Anderson Cancer Center, holding a primary appointment in the Health Services Research Department and a joint appointment in the Breast Medical Oncology Department.
One key goal in developing precision vaccines and immune therapies is to reduce the risk of breast cancer recurrence. Yet currently, there is only one FDA-approved immunotherapy drug for breast cancer, and it benefits just a small subset of women.
In this episode of Investigating Breast Cancer, we talk with Dr. Karen Anderson about vaccines, harnessing the power of a person’s immune system, and reducing the risk of breast cancer recurrence. And of course, we’d all like to know: What’s the progress? And how has COVID-19 impacted this research?
Advances in cancer therapy have dramatically contributed to the decline in breast cancer deaths over the last three decades. But even with these advances, drug resistance—when tumors stop responding to anti-cancer drugs—remains a serious clinical challenge. Dr. Sarat Chandarlapaty talks about the strategies to prevent cancer cells from evading the drugs designed to kill them.
Dr. Chandarlapaty is a laboratory head at the Human Oncology and Pathogenesis Program at the Memorial Sloan Kettering Cancer Center. He's also a BCRF Scientific Advisory Board member and has been a BCRF researcher since 2015.